Nimbus Therapeutics, Inc.
https://www.nimbustx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nimbus Therapeutics, Inc.
J.P. Morgan Day Three: Biogen Still Shopping For Deals, Sanofi Explains Its View On Oncology
Daily notebook from the J.P. Morgan Healthcare Conference: Biogen is still looking for deals, just smaller; Sanofi's push in immunology has pulled it away from oncology; Sage provides updates on Zurzuvae launch; and Takeda plans a big program for its TYK-2 inhibitor.
Deal Watch: Lilly Sends European Commercial Rights For Two Migraine Drugs To Organon
Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.
Eisai And Eli Lilly Triumph At The 19th Annual Scrip Awards
Eisai and Lilly were the biggest winners at the 19th Annual Scrip Awards in a glittering ceremony at the Dorchester in London’s Mayfair, hosted by the actor and comedian Jon Culshaw.
A Month After Lung Cancer Withdrawal, Takeda Gets Approval For New Colorectal Cancer Drug
The US FDA approved Fruzaqla (fruquintinib) for previously treated metastatic disease regardless of biomarker status. The drug, already approved in China, was de-risked when Takeda licensed it from HutchMed.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Drug Discovery Tools
- ADMET
- Bioinformatics
- Other Names / Subsidiaries
-
- Nimbus Discovery LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice